Dexcom Q4 Earnings: Expanding Sales, New Products, Margin Pressure And More
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 14 2025
0mins
Source: Benzinga
Quarterly Performance: Dexcom, Inc. reported a 8% year-over-year revenue increase to $1.114 billion for Q4, surpassing analyst expectations, although adjusted EPS of 45 cents fell short of the consensus estimate of 50 cents.
Future Outlook: The company reaffirmed its FY25 guidance with projected revenue of $4.60 billion and aims to enhance global access to its continuous glucose monitoring products following significant investments in sales force expansion and product launches.
Analyst Views on EKG
Wall Street analysts forecast EKG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EKG is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 19.740
Low
Averages
High
Current: 19.740
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
